Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of duvelisib in relapsed or refractory peripheral T-cell lymphoma
2019-001123-13Phase 2Completed
- Sponsor
- Secura Bio
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of duvelisib in peripheral T-cell lymphoma (PTCL) and T-cell lymphoma, sponsored by Secura Bio. Primary endpoint: Dose Optimization Phase primary endpoints. Started May 2019; status: completed.
02
Drugs
duvelisib
03
Conditions
peripheral T-cell lymphoma (PTCL)T-cell lymphoma
Beyond the preview
Go deeper on 2019-001123-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001123-13.